Showcases Stock ranks Forex

Abbvie Inc (ABBV)
158.02  2.72 (1.75%) 03-24 16:03
Open: 155.28 Pre. Close: 155.3
High: 158.48 Low: 154.59
Volume: 4,583,007 Market Cap: 278,769(M)
Stock Technical Analysis
Target: Six months: 185.10
One year: 216.20
Support: Support1: 151.12
Support2: 146.57
Resistance: Resistance1: 158.48
Resistance2: 185.10
Pivot: 153.61
Moving Averages: MA(5): 155.98
MA(20): 153.90
MA(100): 154.63
MA(250): 150.43
MACD: MACD(12,26): 1.16
Signal(12,26,9): 0.75
%K %D: %K(14,3): 82.40
%D(3): 84.13
RSI: RSI(14): 60.29
52-Week: High: 175.91
Low: 134.09
Change(%): -3.5
Average Vol(K): 3-Month: 6376
10-Days: 9195
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 158.675 - 159.264 159.264 - 159.737
Low: 153.002 - 153.743 153.743 - 154.338
Close: 156.898 - 158.052 158.052 - 158.979
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ ABBV ] has closed below upper band by 10.8%. Bollinger Bands are 6.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Stock chart
Stock News
Sat, 25 Mar 2023
4J Wealth Management LLC makes a $219,000 investment in ... - Best Stocks

Fri, 24 Mar 2023
Traders Buy High Volume of Call Options on AbbVie (NYSE:ABBV) - MarketBeat

Fri, 24 Mar 2023
AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs - Nasdaq

Fri, 24 Mar 2023
FUKOKU MUTUAL LIFE INSURANCE Co Lowers Position in AbbVie ... - MarketBeat

Thu, 23 Mar 2023
AbbVie Inc. (NYSE:ABBV) Position Increased by Carmel Capital ... - MarketBeat

Wed, 22 Mar 2023
US FDA declines to approve AbbVie's Parkinson's disease therapy - Reuters

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 1770.00
Shares Float (M) 1770.00
% Held by Insiders 0.12
% Held by Institutions 71.55
Shares Short (K) 12700
Shares Short Prior Month (K) 10300
Stock Financials
EPS 6.630
Book Value (p.s.) 9.750
Profit Margin 20.39
Operating Margin 38.97
Return on Assets (ttm) 9.9
Return on Equity (ttm) 72.4
Qtrly Rev. Growth 1.6
Gross Profit (p.s.) 23.463
Sales Per Share 32.797
EBITDA (p.s.) 17.565
Qtrly Earnings Growth -38.80
Operating Cash Flow (M) 24940.00
Levered Free Cash Flow (M) 22760.00
Stock Valuation
PE Ratio 23.83
PEG Ratio -5.61
Price to Book value 16.21
Price to Sales 4.82
Price to Cash Flow 11.21
Stock Dividends
Dividend 1.480
Dividend Yield 0.01
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android